Rubicon Research Limited has filed its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE). The company confirmed that the results have been published in the Financial Express (All India Edition) and Loksatta (Mumbai Edition).

The disclosure was made in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Deepashree Tanksale, Company Secretary of Rubicon Research Limited, signed off on the filing on August 15, 2026.

Filing Details

The submission includes copies of the newspaper publications containing the financial results. These documents are also available on the company’s website under the Investors Section.

No specific financial figures, including revenue, net profit, or EBITDA, were provided in the exchange filing notice. Investors are directed to the company’s website for detailed financial statements.

Rubicon Research has convened its 27th Annual General Meeting (AGM) for Wednesday, August 26, 2026, at 1:00 P.M. (IST) via video conferencing, seeking shareholder approval for a final dividend of ₹1.50 per equity share and the strategic merger of its wholly owned subsidiary, KIA Health Tech Private Limited. The meeting represents a critical governance milestone for the pharmaceutical company, which listed on Indian exchanges in October 2025, as it seeks to streamline operations through internal consolidation while rewarding investors with a payout that reflects its strong FY26 financial performance.

The Board of Directors recommended the dividend based on consolidated profit after tax of ₹2,467 million for the financial year ended March 31, 2026. The record date for determining dividend entitlement is fixed for Friday, August 7, 2026. Payment will be made electronically within 30 days of the AGM, subject to applicable tax deduction at source. The total dividend payout is estimated at approximately ₹25 crore, representing a payout ratio of 13.29% of standalone profits after tax.

Key Agenda Items

Beyond the dividend declaration, the AGM notice outlines several special business resolutions aimed at enhancing corporate efficiency and employee retention. The most significant operational change is the proposed Scheme of Merger under Section 233 of the Companies Act, 2013, which will amalgamate KIA Health Tech Private Limited into the parent company. The merger is designed to eliminate duplicate compliance costs, optimize resource utilization, and simplify the corporate structure without issuing new shares or altering the existing shareholding pattern.

The company is also seeking approval for the Rubicon Research Limited Stock Options Plan 2026 (ESOP 2026). This plan creates a pool of 24,84,415 employee stock options, including unutilized options from the previous scheme, to attract and retain talent. Additionally, shareholders will approve revised remuneration for non-executive independent directors, increasing annual fees to ₹3.50 million for the Audit Committee Chairperson and ₹3.00 million for other independent directors, effective October 1, 2026.

Voting and Participation

Remote e-voting will commence on Saturday, August 22, 2026, at 9:00 A.M. (IST) and conclude on Tuesday, August 25, 2026, at 5:00 P.M. (IST). Members holding shares as of the cut-off date, Wednesday, August 19, 2026, are eligible to vote. The facility for appointing proxies is not available for this virtual meeting. M/s. SGGS & Associates has been appointed as the scrutinizer to oversee the e-voting process, ensuring transparency and compliance with SEBI Listing Regulations and the Companies Act, 2013.